Nitrobanzamide useful as antiarrythmic agent
Abstract
Hydrated N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride characterised in that it: (i) comprises water in the range of from 1.7 to 2.4 molar equivalents; and/or (ii) has a melting point above 145 DEG C and/or, (iii) provides an infra red spectrum containing peaks at 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 cm<-1>; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or (v) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II; a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.
Term
Term ended
Projected expiry passed 24 March 2018, 8.5 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
58 members in 38 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 9706376 | United Kingdom | A | |
| 9706376 | United Kingdom | A | |
| 9801913 | European Patent Office (EPO) | W | |
| 9801913 | European Patent Office (EPO) | W | |
| 9706376 | – | – | – |
| EP9801913 | – | – | – |
| GB19970006376 | – | – | – |
| WO1998EP01913 | – | – | – |
Members58
| Document | Office | Kind | |
|---|---|---|---|
| US5455409A | United States of America | A | |
| CA2224168A1 | Canada | A1 | |
| WO9700496A1 | World Intellectual Property Organization (WIPO) | A1 | |
| GB9706376D0 | United Kingdom | D0 | |
| CA2285197A1 | Canada | A1 | |
| WO9843947A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7334198A | Australia | A | |
| PE61799A1 | Peru | A1 | |
| NO994682D0 | Norway | D0 | |
| NO994682L | Norway | L | |
| ZA982558B | South Africa | B | |
| AP9901651A0 | African Regional Intellectual Property Organization (ARIPO) | A0 | |
| ID22787A | Indonesia | A | |
| EP0971882A1 | European Patent Office (EPO) | A1 | |
| TR1999002356T2 | Türkiye | T2 | |
| TR199902356T2 | Türkiye | T2 | |
| EA199900879A1 | Eurasian Patent Organization (EAPO) | A1 | |
| BG103829A | Bulgaria | A | |
| SK130299A3 | Slovakia | A3 | |
| PL335879A1This record | Poland | A1 | |
| CN1257478A | China | A | |
| BR9809054A | Brazil | A | |
| HU0001683A2 | Hungary | A2 | |
| HUP0001683A2 | Hungary | A2 | |
| HK1025089A | Hong Kong, China | A | |
| HK1025089A1 | Hong Kong, China | A1 | |
| UY24937A1 | Uruguay | A1 | |
| KR20010005566A | Republic of Korea | A | |
| IL132042A0 | Israel | A0 | |
| IL132042D0 | Israel | D0 | |
| EG21226A | Egypt | A | |
| NZ337794A | New Zealand | A | |
| CA2224168C | Canada | C | |
| JP2001518088A | Japan | A | |
| AU741476B2 | Australia | B2 | |
| US2001056207A1 | United States of America | A1 | |
| EA002439B1 | Eurasian Patent Organization (EAPO) | B1 | |
| IN188180B | India | B | |
| HU0001683A3 | Hungary | A3 | |
| HUP0001683A3 | Hungary | A3 | |
| EP0971882B1 | European Patent Office (EPO) | B1 | |
| AT228997T | Austria | T | |
| ATE228997T1 | Austria | T1 | |
| DE69809891D1 | Germany | D1 | |
| DZ2452A1 | Algeria | A1 | |
| TW518318B | Taiwan Province of China | B | |
| SK283056B6 | Slovakia | B6 | |
| DK0971882T3 | Denmark | T3 | |
| PT971882E | Portugal | E | |
| US2003083524A1 | United States of America | A1 | |
| OA11200A | African Intellectual Property Organization (OAPI) | A | |
| UA57066C2 | Ukraine | C2 | |
| SI0971882T1 | Slovenia | T1 | |
| ES2189163T3 | Spain | T3 | |
| DE69809891T2 | Germany | T2 | |
| AP1205A | African Regional Intellectual Property Organization (ARIPO) | A | |
| US2004092771A1 | United States of America | A1 | |
| MA26477A1 | Morocco | A1 |
Numbers
- Publication, DOCDB
- 335879
- Publication, EPODOC
- PL335879
- Application
- 98335879
- Application, DOCDB
- 33587998
- Application, EPODOC
- PL19980335879
Titles
- English
- NITROBANZAMIDE USEFUL AS ANTIARRYTHMIC AGENT
Classification
- CPC, 2
- C07C233/78
- A61P9/06
- IPC, 3
- A61K31 166
- C07C233 78
- A61P9 06